Investigation of new biomarkers of kidney injury in renal transplant recipients undergoing graft biopsy.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
09 2021
Historique:
revised: 21 05 2021
received: 30 09 2020
accepted: 23 06 2021
pubmed: 2 7 2021
medline: 11 11 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

Urinary and blood kidney biomarkers (BM) remain insufficient for early kidney injury detection. We aimed to compare new kidney BM with histopathological data in kidney allograft recipients. Blood and urine samples were collected from consecutive adult patients just before graft biopsy. All kidney samples were classified according to the Banff 2007 classification. The diagnostic performance of 16 new BM was compared to those of urinary proteins, blood urea nitrogen, eGFR, and serum creatinine to identify histopathological groups. Two hundred and twenty-three patients were analyzed. Microalbuminuria and urinary proteins performed well to discriminate glomerular injury from slightly modified renal parenchyma (SMRP). Urinary neutrophil gelatinase-associated lipocalin (NGAL) had the best performance relative to SMRP (AUROC .93) for acute tubular necrosis (ATN) diagnosis. Other BM had a slightly lower AUROC (.89). For the comparison of ATN to acute rejection, several new urinary BM (NGAL, cystatin C, MCP1) and classical BM (eGFR, serum creatinine) gave similar AUROC values (from .80 to .85). Urinary NGAL values in patients with ATN were 10-time higher than those with acute rejection (P=.0004). The new BM did not outperform classical BM in the context of renal transplantation. Urinary NGAL may be useful for distinguishing between ATN and acute rejection.

Identifiants

pubmed: 34196434
doi: 10.1111/ctr.14408
doi:

Substances chimiques

Biomarkers 0
Lipocalin-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14408

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Prakash J, Singh M, Tripathi K, et al. Complications of percutaneous renal biopsy. J Indian Med Assoc. 1994;92(12):395-396.
Sundaram R, Abhirama B, Gowtham L, et al. Limitations of conventional parameters and role of urinary protein biomarkers in the determination of drug induced acute kidney injury in very early stage. Br J Pharm Res. 2014;4(21):2463-2474
Mariat C. Diagnostic et suivi de la dysfonction chronique du greffon rénal : du DFG aux nouveaux biomarqueurs. Néphrologie Thérapeutique. 2008;4:S204-S207
Ho J, Rush DN, Nickerson PW. Urinary biomarkers of renal transplant outcome: Curr Opin Organ Transplant. 2015;20(4):476-481
Brott D, Adler S, Arani R, , et al. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des Devel Ther. Published online 2014:8 227-237.
Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45(1):17-23
Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem Int J Biochem Lab Med. 2014;51(3):335-351
Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol. 2010;28(5):436-440
Vanmassenhove J, Vanholder R, Nagler E, et al. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28(2):254-273
Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23(12):2151-2157
Mårtensson J, Martling C-R, Bell M. Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth. 2012;109(6):843-850
Ronco C, Legrand M, Goldstein SL, et al. Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective. Blood Purif. 2014;37(4):271-285
Devarajan P Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Clin Lab Invest. 2008;68(sup241):89-94
Solez K, Colvin RB, Racusen LC, et al. Banff 07 Classification of Renal Allograft Pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760
Gautier J-C, Zhou X, Yang Yi, et al. Evaluation of novel biomarkers of nephrotoxicity in Cynomolgus monkeys treated with gentamicin. Toxicol Appl Pharmacol. 2016;303:1-10
Hoeppe S, Schreiber TD, Planatscher H, et al. Targeting peptide termini, a novel immunoaffinity approach to reduce complexity in mass spectrometric protein identification. Mol Cell Proteomics. 2011;10(2) M110.002857.
Jaffuel A, Lemoine J, Aubert C, et al. Optimization of liquid chromatography-multiple reaction monitoring cubed mass spectrometry assay for protein quantification: application to aquaporin-2 water channel in human urine. J Chromatogr A. 2013;1301:122-130
Simon R, Lemoine J, Fonbonne C, et al. Absolute quantification of podocin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-multiple reaction monitoring cubed mass spectrometry. J Pharm Biomed Anal. 2014;94:84-91
Biarc J, Simon R, Fonbonne C, et al. Absolute quantification of podocalyxin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-mass spectrometry. J Chromatogr A. 2015;1397:81-85
Urizar RE, Cerda J, Godley K, et al. The early diagnosis of glomerulopathy through the detection of subclinical proteinuria: microalbuminuria. N Y State J Med. 1988;88(8):423-426.
Nickolas TL, Forster CS, Sise ME, et al. NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012;82(6):718-722
Ramirez-Sandoval JC, Herrington W, Morales-Buenrostro LE. Neutrophil gelatinase-associated lipocalin in kidney transplantation: a review. Transplant Rev. 2015;29(3):139-144
Lacquaniti A, Caccamo C, Salis P, et al. Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. Biomarkers. 2016;21(4):371-378
Kaufeld JK, Gwinner W, Scheffner I, et al. Urinary NGAL ratio is not a sensitive biomarker for monitoring acute tubular injury in kidney transplant patients: NGAL and ATI in renal transplant patients. J Transplant. 2012;2012:1-8
Moledina DG, Hall IE, Thiessen-Philbrook H, et al. Performance of serum creatinine and kidney injury biomarkers for diagnosing histologic acute tubular injury. Am J Kidney Dis. 2017;70(6):807-816
Yadav B, Prasad N, Agrawal V, et al. Urinary kidney injury molecule-1 can predict delayed graft function in living donor renal allograft recipients: kidney injury molecule and DGF. Nephrology. 2015;20(11):801-806
Kohei J, Ishida H, Kazunari T, et al. Neutrophil gelatinase-associated lipocalin is a sensitive biomarker for the early diagnosis of acute rejection after living-donor kidney transplantation. Int Urol Nephrol. 2013;45(4):1159-1167
Heyne N, Kemmner S, Schneider C, , et al. Urinary neutrophil gelatinase-associated lipocalin accurately detects acute allograft rejection among other causes of acute kidney injury in renal allograft recipients: Transplant J. 2012;93(12):1252-1257
Ramirez-Sandoval JC, Barrera-Chimal J, Simancas PE, et al. Tubular urinary biomarkers do not identify aetiology of acute kidney injury in kidney transplant recipients: AKI biomarkers in kidney transplantation. Nephrology. 2014;19(6):352-358
Seeman T, Vondrak K, Dusek J, et al. Urinary neutrophil gelatinase-associated lipocalin does not distinguish acute rejection from other causes of acute kidney injury in pediatric renal transplant recipients. Clin Lab. 2017;63111-114.

Auteurs

Arthur Michon (A)

Nephrology Department, Bicêtre University Hospital, APHP, Paris, France.

Antoine Durrbach (A)

University Paris Saclay, Paris, France.
INSERM UMRS-1186, Gustave Roussy Institute, Paris, France.
Nephrology Department, Henri Mondor, University Hospital, APHP, Paris, France.

Jean-Charles Gautier (JC)

Preclinical Safety, Sanofi R&D, Paris, France.

Xavier Benain (X)

Biostatistics and Programming, Sanofi R&D, Paris, France.

Catherine Lunven (C)

Clinical Sciences and Operations, Sanofi R&D, Paris, France.

Alexandre Jagerschmidt (A)

Translational Medicine and Early Development, Sanofi R&D, Paris, France.

Catherine Aubert (C)

Biomarkers and Clinical Bioanalyses, Translational Medicine and Early Development, Sanofi R&D, Paris, France.

Oliver Poetz (O)

SIGNATOPE GmbH, Paris, France.
Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Thomas Joos (T)

Biomarkers and Clinical Bioanalyses, Translational Medicine and Early Development, Sanofi R&D, Paris, France.
Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Thierry Gury (T)

Nephrology Department, Henri Mondor, University Hospital, APHP, Paris, France.

Laurent Becquemont (L)

Nephrology Department, Bicêtre University Hospital, APHP, Paris, France.
University Paris Saclay, Paris, France.
CESP/INSERM U1018 (Centre de Recherche en Épidémiologie et Santé des Populations), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH